• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

byMatthew GrowdonandShaidah Deghan, MSc. MD
November 11, 2015
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

 

1. Over a median follow-up of 11.9 years, among patients with stable ischemic heart disease, there was no significant difference in long-term mortality between patients treated with medical therapy alone versus patients treated with the combination of percutaneous coronary intervention (PCI) and medical therapy.

2. This study extends the findings from the original Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial from a median of 4.6 years to 11.9 years of follow-up.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: PCI is a cornerstone of the management of ST-segment and non-ST-segment elevation myocardial infarction given previous research linking this intervention to improved survival rates. However, the long-term survival benefit of PCI in patients with stable ischemic heart disease is uncertain. In the previously published COURAGE trial, there was no significant difference between optimal medical therapy alone and PCI with medical therapy in this population of patients over a median follow-up of 4.6 years.

In this study, a sub-cohort comprising 53% of the original COURAGE sample was followed for 15 years; the long-term survival benefit of medical therapy alone versus the combination of PCI and medical therapy was compared. During a median follow-up period of 11.9 years, there was once again no significant difference in all-cause mortality between the two groups. This finding was consistent across different subgroup analyses based on age, smoking status, gender, and multiple prior comorbidities.

RELATED REPORTS

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

Optical coherence tomography-guided angioplasty reduces adverse events compared to angiography guidance

#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics

The strength of this study is the consistency of findings from the original COURAGE cohort across a longer follow-up period. However, the findings are limited by a number of factors including the fact that the findings pertain only to half of the original COURAGE cohort and that the trial provides little information about newer devices and technologies employed during PCI.

Click to read the study, published today in NEJM

Relevant Reading:  Optimal medical therapy with or without PCI for stable coronary disease

In-Depth [randomized controlled trial]: This study involved 1211 patients (53% of the original population) from the COURAGE cohort who were followed for a median of 11.9 years in total (range 0 to 15). 25% of study population died during follow-up. The unadjusted HR comparing the combination of PCI with medical therapy group to medical therapy alone group was 0.98 (95% [CI], 0.83 to 1.15, P=0.77). When adjusted by baseline variables of significance, the HR was 1.03 (95% [CI], 0.83 to 1.21; P=0.76). The unadjusted comparison between outcomes in the whole study cohort remained nonsignificant across a number of important subgroup analyses including whether or not there was extended follow-up, age, smoking status, sex, multivessel CAD status, and prior conditions (including diabetes, liver disease, kidney disease).

There were numerous significant differences between the patients who were and were not followed in the extended period; however, only one of these factors (incidence of pulmonary disease in the cohort with extended follow-up) differed significantly between the two groups. The differences were driven in large part by the fact that no Canadian patients were available in extended follow-up.

Image: CC/Patrick J. Lynch

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Coronary artery disease
Previous Post

Clinically undetected myocardial scars detected by cardiac MRI

Next Post

Endovascular thrombectomy improves functional outcomes but not mortality in acute ischemic stroke

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Cardiology

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

February 28, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Optical coherence tomography-guided angioplasty reduces adverse events compared to angiography guidance

October 1, 2024
#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics
StudyGraphics

#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics

September 10, 2024
#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke
StudyGraphics

#VisualAbstract: Long-term Colchicine Does Not Reduce Recurrent Events Following Ischemic Stroke

August 15, 2024
Next Post

Endovascular thrombectomy improves functional outcomes but not mortality in acute ischemic stroke

Metronome use linked to rate optimization in pediatric CPR

No benefit of continuous over interrupted chest compressions during CPR

Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis

Adjunctive ultrasonography increases detection rate of early breast cancer [J-START trial]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Worsening kidney function observed following SARS-CoV-2 infection in children
  • 2MM: AI Roundup – FDA’s AI Push, Trial Speedups with Real-World Data, Smart Surgical Monitors, and Regulatory Overhaul Begins [May 23rd, 2025]
  • Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.